Andrew Radin orchestrates his AI discovery platform's pivot to R&D with a harmonious name change and eyes on the clinic

Nicole DeFeudis

Editor

Andrew Radin was a straight A student. So when he stopped turning in assignments in Nigam Shah’s class at Stanford University, the professor knew something …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Andrew Radin orchestrates his AI discovery platform's pivot to R&D with a harmonious name change and eyes on the clinic

Nicole DeFeudis

Editor

Sign up to read this article for free.

Moderna reports slow start to RSV sales as Bancel steps back from commercial role

Sarepta discontinues work on next-gen exon-skipping drug for Duchenne

Biotech industry worries over potential for RFK Jr. ally as FDA pick

GSK CEO Emma Walmsley on the new Trump administration, trust, AI and China

Joe Jimenez's latest Aditum company lines up T cell engager from China

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

An­drew Radin or­ches­trates his AI dis­cov­ery plat­for­m's piv­ot to R&D with a har­mo­nious name change and eyes on the clin­ic

Nicole DeFeudis

Editor

Sign up to read this article for free.

Mod­er­na re­ports slow start to RSV sales as Ban­cel steps back from com­mer­cial role

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

Joe Jimenez's lat­est Adi­tum com­pa­ny lines up T cell en­gager from Chi­na

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Andrew Radin orchestrates his AI discovery platform's pivot to R&D with a harmonious name change and eyes on the clinic

Moderna reports slow start to RSV sales as Bancel steps back from commercial role

Sarepta discontinues work on next-gen exon-skipping drug for Duchenne

Biotech industry worries over potential for RFK Jr. ally as FDA pick

GSK CEO Emma Walmsley on the new Trump administration, trust, AI and China

Joe Jimenez's latest Aditum company lines up T cell engager from China

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks